MGC Pharmaceuticals Ltd
ASX:MXC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MGC Pharmaceuticals Ltd
Income from Continuing Operations
MGC Pharmaceuticals Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MGC Pharmaceuticals Ltd
ASX:MXC
|
Income from Continuing Operations
-AU$17.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-44%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Income from Continuing Operations
-AU$30.3m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Income from Continuing Operations
-AU$90.1m
|
CAGR 3-Years
26%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Income from Continuing Operations
AU$30.4m
|
CAGR 3-Years
449%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Income from Continuing Operations
-AU$64.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Income from Continuing Operations
AU$10.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
MGC Pharmaceuticals Ltd
Glance View
MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is primarily focused on producing standardized, phytocannabinoid and plant-derived medicines. The Company’s Nature to Medicine strategy comprises the entire supply chain, from botanical research, to develop new strains of Cannabis Sativa, preclinical and clinical research, product manufacturing, distribution, as well as the development of drug delivery systems. The Group has also completed a Phase II double-blind, randomized, placebo controlled clinical trial in Israel and India, to evaluate the safety and efficacy of a natural anti-inflammatory based formulation ArtemiC on patients diagnosed with Corona Virus Disease 2019 (COVID-19).
See Also
What is MGC Pharmaceuticals Ltd's Income from Continuing Operations?
Income from Continuing Operations
-17.2m
AUD
Based on the financial report for Dec 31, 2023, MGC Pharmaceuticals Ltd's Income from Continuing Operations amounts to -17.2m AUD.
What is MGC Pharmaceuticals Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-44%
Over the last year, the Income from Continuing Operations growth was 29%. The average annual Income from Continuing Operations growth rates for MGC Pharmaceuticals Ltd have been -10% over the past three years , -19% over the past five years , and -44% over the past ten years .
